Reviva Shares Slump 32% After FDA Mandates New Phase 3 Trial for Brilaroxazine

Introduction

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) is a clinical-stage company based in Cupertino, California, that applies chemical genomics–driven technology to discover and develop therapies for central nervous system, respiratory, and metabolic diseases. Its lead candidate, brilaroxazine (RP5063), is being evaluated for multiple neuropsychiatric indications, including schizophrenia and Alzheimer’s disease-related psychosis.

Corporate Structure

The company employs between 11 and 50 individuals, including a leadership team with advanced degrees in pharmaceutical sciences. Laxminarayan Bhat, Ph.D., serves as Founder, President, and CEO. Reviva’s internal research platform supports two new chemical entities: brilaroxazine (RP5063) and RP1208, a triple reuptake inhibitor currently in preclinical development.

Reviva Pharmaceuticals by Michał Parzuchowski

Recent Developments and News

On November 12, 2025, Reviva disclosed feedback from an FDA pre-New Drug Application (NDA) meeting, which recommended a second Phase 3 trial of brilaroxazine for schizophrenia prior to NDA submission. The company is preparing for this meeting in Q4 2025, with a potential NDA submission targeted for Q2 2026.
On November 13, 2025, Reviva reported its financial results for the third quarter ending September 30, 2025, highlighting:

• The granting of European Patent EP3749324 covering brilaroxazine for the treatment of pulmonary fibrosis.
• The completion of a one-year Phase 3 RECOVER open-label extension study, showing sustained efficacy across key schizophrenia symptom scales and an overall benign safety profile.

On December 12, 2025, Nasdaq filed a Form 25 to remove warrants expiring December 14, 2025, from listing and registration. Two beneficial ownership disclosures were filed in mid-December: a Schedule 13D/A on December 22, 2025, indicating Vedanta Partners, LLC holds 4.4% of common shares and Parag Saxena aggregates 5.2%, along with an 8-K on December 23, 2025, which did not include additional financial metrics.

Financial and Strategic Analysis

As of December 23, 2025, Reviva’s stock price stood at $0.40, reflecting a decline of 32.20% on that day, with a trading volume of 2,276,065 shares. Key financial and trading metrics include:

Metric	Value
Price (2025-12-23)	$0.40
Daily Change	–32.20%
Volume	2,276,065
52-Week Range	$0.25 – $2.17
Market Capitalization	$67.88 M
Cash (most recent quarter)	$13.18 M
Net Income (TTM)	–$22.76 M
EPS (TTM)	–0.44

Strategically, Reviva is focusing on filing a New Drug Application for brilaroxazine in schizophrenia by mid-2026, leveraging its recently granted European patent and existing protections in the U.S., China, and Japan. The company holds Orphan Drug Designation for idiopathic pulmonary fibrosis and is preparing for a pivotal second Phase 3 study, as advised by the FDA.

Market Position and Industry Context

Reviva operates within a competitive landscape of clinical-stage biotech firms targeting large markets in central nervous system and fibrotic diseases. Its approach—modulating serotonin and dopamine systems with once-daily dosing—aims to address needs in psychiatric care. The small-cap company benefits from patent exclusivity and orphan status in select indications but faces sector risks, including regulatory hurdles, trial outcomes, and market acceptance challenges. Significant shareholders such as Vedanta Partners and Parag Saxena may influence future governance and financing decisions.

TL;DR

As of December 23, 2025, RVPH shares traded at $0.40 following a 32.20% drop. Reviva is preparing for an FDA pre-NDA meeting in Q4 2025 and aims to submit an NDA for brilaroxazine in schizophrenia by Q2 2026. The company holds a new European patent for pulmonary fibrosis and completed a one-year Phase 3 extension demonstrating sustained efficacy and a favorable safety profile. Warrants maturing December 14, 2025, were delisted, and key investors now hold over 9% of shares collectively.